Radiopharmaceutical CDMO Market Revenue to Attain USD 8.50 Bn by 2035

Published: 19 Jan 2026

Author: Precedence Research

Share:

Radiopharmaceutical CDMO Market Revenue and Trends 2026 to 2035

The global radiopharmaceutical CDMO market revenue reached USD 3.24 billion in 2025 and is predicted to attain around USD 8.50 billion by 2035 with a CAGR of 10.12%. The market's growth is driven by several factors, including the rising trend of outsourcing and the increasing innovations in nuclear medicine.

What are the Factors That Have a Significant Contribution to the Growth of the radiopharmaceutical CDMO market?

The increasing burden of cancer and growing demand for personalized treatment (theranostics) are the major drivers, accelerating the growth of the market in the coming years. The shift toward precision medicine in oncology, with the rise of theranostics, significantly increases the need for specialized manufacturing capabilities that CDMOs provide. Several pharmaceutical companies are increasingly outsourcing production to leverage the specialized infrastructure and expertise of CDMOs, which reduces cost and accelerates time-to-market.  Additionally, the complex and stringent regulatory requirements for handling radioactive materials make CDMOs with GMP-qualified facilities, which propel the growth of the radiopharmaceutical CDMO market during the forecast period.

Radiopharmaceutical CDMO Market Coverage

Segment Insights

By radioisotope type, the fluorine-18 segment accounted for the majority of the 34% market share in 2025, owing to its increasing use in positron emission tomography (PET) imaging for oncology applications. Its characteristics make it highly effective for both research and clinical use. Fluorine-18 is used to detect tumors, assess treatment response, and monitor cancer progression by visualizing glucose utilization in tissues.

By application, the diagnostic radiopharmaceuticals segment contributed the highest market share of 62% in 2025. Diagnostic radiopharmaceuticals are radioactive drugs that are widely used in nuclear medicine to image the function of organs and tissues, helping to diagnose diseases or disorders.

By service type, the contract manufacturing segment led the market and held approximately 48% market share in 2025. The growth of the segment is driven by the rising outsourcing of both regular production and large-scale manufacturing, as this is cost-effective, complies with the stringent regulatory environments, and provides access to radiation-shielded facilities.

By therapeutic area, the oncology segment captured the highest market share of 71% in 2025, owing to the rising use of theranostic therapies for patients with cancer. The unmet needs in cancer treatment and the rapid advancement of the clinical pipeline are fueling the use of radiation through oncology initiatives supported by CDMOs.

Regional Insights

North America holds the dominant share in the global radiopharmaceutical CDMO market. The region benefits from a robust ecosystem where companies outsource complex manufacturing to specialized CDMOs for personalized medicine and diagnostics. The region’s growth is driven by its sophisticated healthcare infrastructure, increasing burden of cancer, and favorable FDA regulations. The constant innovation in radioisotope production and imaging technologies is rapidly expanding the applications and efficacy of radiopharmaceuticals in the region. Additionally, the increasing acceptance of theranostics and the development of new radiopharmaceuticals being produced from isotopes are anticipated to fuel the expansion of the region in the coming years. 

On the other hand, the Asia Pacific region is anticipated to grow at the fastest rate in the market during the forecast period. The fastest growth of the region is attributed to the expanding healthcare infrastructure, rising investments in diagnostic infrastructure, increasing adoption of PET/SPECT imaging, surging cases of chronic diseases, growing demand for precision medicine (theranostics), and supportive government initiatives for upgrading healthcare infrastructure. Several pharmaceutical companies often rely on CDMOs for the complex development and scaled manufacturing of radiopharmaceuticals. Such a combination of factors is expected to boost the market’s growth in the Asia Pacific region.

Recent Developments

• In January 2025, Lantheus, a US-based radiopharmaceutical company, announced a definitive agreement to acquire clinical-stage radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics. The company makes an upfront payment of USD 250 million, with the potential for an additional $752.5m in milestone payments. The acquisition provides Lantheus access to Evergreen’s radioligand therapy (RLT) manufacturing infrastructure, which includes a revenue-generating contract manufacturing business. (Source: https://www.pharmaceutical-technology.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7320

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344